Cargando…
(Arg)(9)-SH2 superbinder: a novel promising anticancer therapy to melanoma by blocking phosphotyrosine signaling
BACKGROUND: Melanoma is a malignant tumor with high misdiagnosis rate and poor prognosis. The bio-targeted therapy is a prevailing method in the treatment of melanoma; however, the accompanying drug resistance is inevitable. SH2 superbinder, a triple-mutant of the Src Homology 2 (SH2) domain, shows...
Autores principales: | Liu, An-dong, Xu, Hui, Gao, Ya-nan, Luo, Dan-ni, Li, Zhao-feng, Voss, Courtney, Li, Shawn S. C., Cao, Xuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6034221/ https://www.ncbi.nlm.nih.gov/pubmed/29976230 http://dx.doi.org/10.1186/s13046-018-0812-5 |
Ejemplares similares
-
Blockade of phosphotyrosine pathways suggesting SH2 superbinder as a novel therapy for pulmonary fibrosis
por: Wang, Meng, et al.
Publicado: (2022) -
Identification and characterization of a large family of superbinding bacterial SH2 domains
por: Kaneko, Tomonori, et al.
Publicado: (2018) -
Aptamer‐SH2 superbinder‐based targeted therapy for pancreatic ductal adenocarcinoma
por: Liu, An‐Dong, et al.
Publicado: (2021) -
Specificity and regulation of phosphotyrosine signaling through SH2 domains
por: Marasco, Michelangelo, et al.
Publicado: (2020) -
IQGAP1 Is a Phosphotyrosine-Regulated Scaffold for SH2-Containing Proteins
por: Thines, Louise, et al.
Publicado: (2023)